Posted by Michael Wonder on 17 Jan 2022
$421,000 cancer drug Kymriah becomes eligible for reimbursement
14 January 2022 - Novartis’ breakthrough cancer treatment Kymriah (ingredient: tisagenlecleucel), which costs over 500 million won (US$421,000), has become eligible for reimbursement, the health insurance review agency said.
In October, the Cancer Review Committee set two indications as the criteria for Kymriah reimbursement -- diffuse large B-cell lymphoma in adults and B-cell acute lymphoblastic leukaemia in children and young adults. Then, the treatment passed the review of the Drug Reimbursement Evaluation Committee this year.
